id: NEW:her2_low_tumor_status_to_NEW:breast_cancer_mortality
name: HER2-Low Tumor Status â†’ Breast Cancer Mortality
from_node:
  node_id: NEW:her2_low_tumor_status
  node_name: HER2-Low Tumor Status
to_node:
  node_id: NEW:breast_cancer_mortality
  node_name: Breast Cancer Mortality
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: HER2-low expression identifies a subset of HR+ metastatic breast cancer with distinct biological
  behavior'
- 'Step 2: Reduced efficacy of CDK 4/6 inhibitors in HER2-low tumors leads to earlier disease progression'
- 'Step 3: Disease progression is associated with increased tumor burden and metastatic spread'
- 'Step 4: Advanced disease burden contributes to higher mortality risk in HER2-low patients'
evidence:
  quality_rating: A
  n_studies: 5
  primary_citation: 'D. Guven and TK Sahin 2024. "The association between HER2-low status and survival
    in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors:
    a systematic review and meta-analysis." https://doi.org/10.1007/s10549-023-07226-1'
  supporting_citations:
  - Additional citations require full-text access - pooled analysis included 5 studies for OS
  - Studies searched from Pubmed, Web of Science, and Scopus databases through August 2023
  - Studies reported survival outcomes according to HER2 expression status
  doi: 10.1007/s10549-023-07226-1
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: HER2-low tumor status is associated with a 22% higher risk of death compared to HER2-zero
  tumors in patients with HR+ metastatic breast cancer treated with CDK 4/6 inhibitors, although this
  analysis was limited by short follow-up duration.
quantitative_effects:
  effect_size:
    value: 1.22
    type: hazard_ratio
    ci_lower: 1.04
    ci_upper: 1.44
  p_value: 0.01
moderators:
- name: Follow-up duration
  direction: strengthens
  strength: moderate
  description: Short median follow-up may underestimate the true mortality difference; longer follow-up
    could reveal larger effect
structural_competency:
  equity_implications: The identification of HER2-low as a prognostic biomarker has implications for healthcare
    system organization and equity. Ensuring universal access to appropriate HER2 testing methodology
    and novel targeted therapies for HER2-low disease is essential. Structural barriers to specialized
    oncology care, biomarker testing, and newer therapeutics may disproportionately affect marginalized
    populations.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.891579'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
